+21.1%
NEE vs MRNA
+511.3%
-490.2%
-15.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.7% | -2.2% | +1.5% | -0.7% |
| 7D | +1.9% | +5.5% | -3.5% | +1.9% |
| 30D | -2.2% | +158.7% | -160.9% | -2.6% |
| 3M | -1.2% | +182.1% | -183.3% | -1.8% |
| 6M | -8.6% | +151.8% | -160.4% | -8.9% |
| YTD | +6.2% | +393.6% | -387.4% | +2.5% |
| 1Y | +21.1% | +499.5% | -478.4% | +15.3% |
| All | +21.1% | +511.3% | -490.2% | +15.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling